-$0.04 Earnings Per Share Expected for Intellipharmaceutics International Inc. (IPCI) This Quarter

Analysts expect that Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSE:I) will announce ($0.04) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Intellipharmaceutics International’s earnings, with the lowest EPS estimate coming in at ($0.10) and the highest estimate coming in at $0.03. Intellipharmaceutics International reported earnings per share of ($0.14) in the same quarter last year, which suggests a positive year-over-year growth rate of 71.4%. The company is scheduled to report its next earnings report on Friday, February 9th.

On average, analysts expect that Intellipharmaceutics International will report full year earnings of ($0.21) per share for the current financial year, with EPS estimates ranging from ($0.31) to ($0.11). For the next financial year, analysts anticipate that the company will post earnings of $0.10 per share, with EPS estimates ranging from ($0.32) to $0.51. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that follow Intellipharmaceutics International.

IPCI has been the topic of a number of research analyst reports. Maxim Group reissued a “buy” rating and issued a $6.00 price target on shares of Intellipharmaceutics International in a report on Friday, June 30th. ValuEngine lowered shares of Intellipharmaceutics International from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. Zacks Investment Research lowered shares of Intellipharmaceutics International from a “buy” rating to a “hold” rating in a report on Wednesday, July 5th. Finally, Mackie raised shares of Intellipharmaceutics International to a “hold” rating and increased their price target for the stock from $1.00 to $3.10 in a report on Tuesday, September 26th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $3.78.

ILLEGAL ACTIVITY WARNING: “-$0.04 Earnings Per Share Expected for Intellipharmaceutics International Inc. (IPCI) This Quarter” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece on another site, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.com-unik.info/2017/10/13/0-04-earnings-per-share-expected-for-intellipharmaceutics-international-inc-ipci-this-quarter.html.

An institutional investor recently raised its position in Intellipharmaceutics International stock. Argent Trust Co increased its holdings in Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSE:I) by 52.5% in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 59,693 shares of the company’s stock after purchasing an additional 20,556 shares during the period. Argent Trust Co owned approximately 0.20% of Intellipharmaceutics International worth $125,000 as of its most recent SEC filing. Institutional investors and hedge funds own 4.24% of the company’s stock.

Intellipharmaceutics International Company Profile

Intellipharmaceutics International Inc is a Canada-based pharmaceutical company engaged in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals.

Get a free copy of the Zacks research report on Intellipharmaceutics International (IPCI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

What are top analysts saying about Intellipharmaceutics International Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Intellipharmaceutics International Inc. and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit